BDNF as a pharmacogenetic target for antipsychotic treatment of schizophrenia
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Antipsychotic drugs remain the mainstay of pharmacotherapy for schizophrenia. As there are large individual variations in efficacy and side-effects of antipsychotic drugs, there is a strong demand for personalized medication to treat schizophrenia. Pharmacogenetic research into antipsychotic drugs has examined a number of genetic variants and only a few polymorphisms have been found which promise to be associated with the therapeutic efficacy and side-effects of antipsychotic drugs. Brain-derived neurotrophic factor (BDNF) is a neurotrophin that plays a major role in neurogenesis and neuroplasticity, and in the modulation of several neurotransmitter systems including the dopaminergic system involved in the pathophysiology of schizophrenia. This review focused on the association between the BDNF gene Val66Met polymorphism and antipsychotic drugs. The BDNF Val66Met polymorphism has been related to the pathophysiology of schizophrenia, psychotic symptomatology, cognition, efficacy and side-effects of antipsychotic drugs. The BDNF Val66Met variants could be a promising target for antipsychotic medication options or developing next generation antipsychotic drugs. However, some studies showed inconsistent results due to sample size, ethnic differences and different antipsychotic drugs. Further studies will be required in this area to confirm the effect of the BDNF Val66Met polymorphism in the pathophysiology of schizophrenia and patients' response to antipsychotic drugs, especially in a larger sample size and in different ethnic populations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gratacòs, M., González, J. R., Mercader, J. M., de Cid, R., Urretavizcaya, M., & Estivill, X. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.08.025 · Cited by 428
Ray, M. T., Shannon Weickert, C., & Webster, M. J. (2014) · Translational Psychiatry · doi:10.1038/tp.2014.26 · Cited by 161
Nikolac Perkovic, M., Nedic Erjavec, G., Zivkovic, M., Sagud, M., Uzun, S., Mihaljevic-Peles, A., Kozumplik, O., Muck-Seler, D., & Pivac, N. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3515-4 · Cited by 35
Research works printed but not linked: 51
- Angelucci, 2000, Brain-derived neurotrophic factor and tyrosine kinase receptor TrkB in rat brain are significantly altered after haloperidol and risperidone administration, J. Neurosci. Res., 60, 783, 10.1002/1097-4547(20000615)60:6<783::AID-JNR11>3.0.CO;2-M · DOI
- Anttila, 2005, Lack of association between two polymorphisms of brain-derived neurotrophic factor and response to typical neuroleptics, J. Neural Transm., 112, 885, 10.1007/s00702-004-0233-9 · DOI
- Bast, 2011, The hippocampal learning-behavior translation and the functional significance of hippocampal dysfunction in schizophrenia, Curr. Opin. Neurobiol., 21, 492, 10.1016/j.conb.2011.01.003 · DOI
- Bonaccorso, 2015, The brain-derived neurotrophic factor (BDNF) Val66Met polymorphism is associated with increased body mass index and insulin resistance measures in bipolar disorder and schizophrenia, Bipolar Disord., 17, 528, 10.1111/bdi.12294 · DOI
- Burghardt, 2012, The influence of the brain‐derived neurotropic factor Val66Met‐Genotype and HMG‐CoA reductase inhibitors on insulin resistance in the schizophrenia and bipolar populations, Clin. Transl. Sci., 5, 486, 10.1111/cts.12001 · DOI
- Chen, 2017, Molecular mechanisms of antipsychotic drug-induced diabetes, Front. Neurosci., 11, 10.3389/fnins.2017.00643 · DOI · Paper page
- Dempster, 2005, Association between BDNF val66 met genotype and episodic memory, Am. J. Med. Genet. Part B: Neuropsych. Genet., 134, 73, 10.1002/ajmg.b.30150 · DOI · Paper page
- Deng, 2013, Effects of antipsychotic medications on appetite, weight, and insulin resistance, Endocrinol. Metab. Clin. North Am., 42, 545, 10.1016/j.ecl.2013.05.006 · DOI · Paper page
- Egan, 2003, The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function, Cell, 112, 257, 10.1016/S0092-8674(03)00035-7 · DOI · Paper page
- Elie, 2010, Cognitive effects of antipsychotic dosage and polypharmacy: a study with the BACS in patients with schizophrenia and schizoaffective disorder, J. Psychopharmacol., 24, 1037, 10.1177/0269881108100777 · DOI · Paper page
- Freyberg, 2017, Intrinsic and antipsychotic drug-induced metabolic dysfunction in schizophrenia, Front. Neurosci., 11, 10.3389/fnins.2017.00432 · DOI
- González-Pinto, 2010, Increase in brain-derived neurotrophic factor in first episode psychotic patients after treatment with atypical antipsychotics, Int. Clin. Psychopharmacol., 25, 241, 10.1097/YIC.0b013e328338bc5a · DOI · Paper page
- Guillin, 2001, BDNF controls dopamine D3 receptor expression and triggers behavioural sensitization, Nature, 411, 86, 10.1038/35075076 · DOI · Paper page
- Han, 2008, Effects of brain-derived neurotrophic factor–catecholamine-O-methyltransferase gene interaction on schizophrenic symptoms, Neuroreport, 19, 1155, 10.1097/WNR.0b013e32830867ad · DOI
- Hashim, 2012, Brain-derived neurotrophic factor Val66Met polymorphism and obsessive-compulsive symptoms in Egyptian schizophrenia patients, J. Psychiatr. Res., 46, 762, 10.1016/j.jpsychires.2012.03.007 · DOI
- Hong, 2003, An association study of a brain-derived neurotrophic factor Val66Met polymorphism and clozapine response of schizophrenic patients, Neurosci. Lett., 349, 206, 10.1016/S0304-3940(03)00828-0 · DOI
- Kang, 2008, No association between the brain-derived neurotrophic factor gene Val66Met polymorphism and tardive dyskinesia in schizophrenic patients, Prog. Neuro-Psychopharmacol. Biol. Psychiatry, 32, 1545, 10.1016/j.pnpbp.2008.05.016 · DOI
- Kheirollahi, 2016, Brain-derived neurotrophic factor Gene Val66Met polymorphism and risk of schizophrenia: a meta-analysis of case–control studies, Cell. Mol. Neurobiol., 36, 1, 10.1007/s10571-015-0229-z · DOI
- Koolschijn, 2010, Effects of brain‐derived neurotrophic factor Val66Met polymorphism on hippocampal volume change in schizophrenia, Hippocampus, 20, 1010, 10.1002/hipo.20699 · DOI
- Lieberman, 2005, Effectiveness of antipsychotic drugs in patients with chronic schizophrenia, N. Engl. J. Med., 2005, 1209, 10.1056/NEJMoa051688 · DOI · Paper page
- Liou, 2004, Association analysis of the dopamine D3 receptor gene ser9gly and brain-derived neurotrophic factor gene val66met polymorphisms with antipsychotic-induced persistent tardive dyskinesia and clinical expression in Chinese schizophrenic patients, Neuromol. Med., 5, 243, 10.1385/NMM:5:3:243 · DOI
- Lohoff, 2010, Pharmacogenetic considerations in the treatment of psychiatric disorders, Expert Opin. Pharmacother., 11, 423, 10.1517/14656560903508762 · DOI
- Mezquida, 2016, Association of the brain-derived neurotrophic factor Val66Met polymorphism with negative symptoms severity, but not cognitive function, in first-episode schizophrenia spectrum disorders, Eur. Psychiatry, 38, 61, 10.1016/j.eurpsy.2016.04.011 · DOI
- Miura, 2014, BDNF Val66Met polymorphism and antipsychotic-induced tardive dyskinesia occurrence and severity: a meta-analysis, Schizophr. Res., 152, 365, 10.1016/j.schres.2013.12.011 · DOI
- Monteleone, 2006, The 196G/A (val66met) polymorphism of the BDNF gene is significantly associated with binge eating behavior in women with bulimia nervosa or binge eating disorder, Neurosci. Lett., 406, 133, 10.1016/j.neulet.2006.07.040 · DOI
- Nieto, 2013, BDNF and schizophrenia: from neurodevelopment to neuronal plasticity, learning, and memory, Front. Psychiatry, 4, 45, 10.3389/fpsyt.2013.00045 · DOI · Paper page
- Notaras, 2015, A role for the BDNF gene Val66Met polymorphism in schizophrenia? A comprehensive review, Neurosci. Biobehav. Rev., 51, 15, 10.1016/j.neubiorev.2014.12.016 · DOI
- Rizos, 2011, Association of serum BDNF levels with hippocampal volumes in first psychotic episode drug-naive schizophrenic patients, Schizophr. Res., 129, 201, 10.1016/j.schres.2011.03.011 · DOI
- Rybakowski, 2006, Prefrontal cognition in schizophrenia and bipolar illness in relation to Val66Met polymorphism of the brain‐derived neurotrophic factor gene, Psychiatry Clin. Neurosci., 60, 70, 10.1111/j.1440-1819.2006.01462.x · DOI · Paper page
- Stubbs, 2015, The prevalence and predictors of type two diabetes mellitus in people with schizophrenia: a systematic review and comparative meta-analysis, Acta Psychiatr. Scand., 10.1111/acps.12439 · DOI · Paper page
- Suchanek, 2013, BDNF val66met polymorphism is associated with age at onset and intensity of symptoms of paranoid schizophrenia in a Polish population, J. Neuropsych. Clin. Neurosci., 25, 88, 10.1176/appi.neuropsych.11100234 · DOI · Paper page
- Takeuchi, 2011, Association of genetic variants for susceptibility to obesity with type 2 diabetes in Japanese individuals, Diabetologia, 54, 1350, 10.1007/s00125-011-2086-8 · DOI
- Tan, 2005, Effect of the BDNF Val66Met genotype on episodic memory in schizophrenia, Schizophr Res, 77, 355, 10.1016/j.schres.2005.03.012 · DOI
- Vasic, 2012, Cerebrospinal fluid biomarker candidates of schizophrenia: where do we stand?, Eur. Arch. Psychiatry Clin. Neurosci., 262, 375, 10.1007/s00406-011-0280-9 · DOI
- Waln, 2013, An update on tardive dyskinesia: from phenomenology to treatment, Tremor Other Hyperkinetic Movements, 3, 10.5334/tohm.165 · doi:10.5334/tohm.165
- Wang, 2009, Decreased levels of serum brain-derived neurotrophic factor in drug-naïve first-episode schizophrenia: relationship to clinical phenotypes, Psychopharmacology, 207, 375, 10.1007/s00213-009-1665-6 · DOI
- Waterhouse, 2009, New insights into the role of brain-derived neurotrophic factor in synaptic plasticity, Mol. Cell. Neurosci., 42, 81, 10.1016/j.mcn.2009.06.009 · DOI · Paper page
- Xiu, 2010, Serum BDNF levels are determined by functional polymorphism Val66Met and associated with cognitive impairment in chronic schizophrenia, Schizophr. Res., 117, 386, 10.1016/j.schres.2010.02.694 · DOI
- Zai, 2012, The role of brain-derived neurotrophic factor (BDNF) gene variants in antipsychotic response and antipsychotic-induced weight gain, Prog. Neuro-Psychopharmacol. Biol. Psychiatry, 39, 96, 10.1016/j.pnpbp.2012.05.014 · DOI
- Zakharyan, 2014, Brain-derived neurotrophic factor blood levels are decreased in schizophrenia patients and associate with rs6265 genotypes, Clin. Biochem., 47, 1052, 10.1016/j.clinbiochem.2014.03.021 · DOI
- Zakharyan, 2011, Functional variants of the genes involved in neurodevelopment and susceptibility to schizophrenia in an Armenian population, Hum. Immunol., 72, 746, 10.1016/j.humimm.2011.05.018 · DOI
- Zhang, 2017, Metabolic adverse effects of olanzapine on cognitive dysfunction: a possible relationship between BDNF and TNF-alpha, Psychoneuroendocrinology, 81, 138, 10.1016/j.psyneuen.2017.04.014 · DOI
- Zhang, 2013, Efficacy and safety of individual second-generation vs. first-generation antipsychotics in First-episode psychosis: a systematic review and meta-analysis, Int. J. Neuropsychopharmacol., 16, 1205, 10.1017/S1461145712001277 · DOI · Paper page
- Zhang, 2013, Genetic variation in BDNF is associated with antipsychotic treatment resistance in patients with schizophrenia, Schizophr. Res., 146, 285, 10.1016/j.schres.2013.01.020 · DOI
- Zhang, 2016, Pharmacogenetic associations of antipsychotic drug-related weight gain: a systematic review and meta-analysis, Schizophr. Bull., 42, 1418, 10.1093/schbul/sbw058 · DOI · Paper page
- Zhang, 2011, Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction, Expert Opinion Drug Metabol. Toxicol., 7, 9, 10.1517/17425255.2011.532787 · DOI · Paper page
- Zhang, 2016, Interaction of BDNF with cytokines in chronic schizophrenia, Brain Behav. Immun., 51, 169, 10.1016/j.bbi.2015.09.014 · DOI
- Zhang, 2012, Cognitive and serum BDNF correlates of BDNF Val66Met gene polymorphism in patients with schizophrenia and normal controls, Hum. Genet., 131, 1187, 10.1007/s00439-012-1150-x · DOI
- Zhang, 2012, Brain-derived neurotrophic factor levels and its Val66Met gene polymorphism predict tardive dyskinesia treatment response to Ginkgo biloba, Biol. Psychiatry, 72, 700, 10.1016/j.biopsych.2012.04.032 · DOI
- Zhang, 2008, BDNF levels and genotype are associated with antipsychotic-induced weight gain in patients with chronic schizophrenia, Neuropsychopharmacology, 33, 2200, 10.1038/sj.npp.1301619 · DOI
- Zhang, 2018, Brain-derived neurotrophic factor as a biomarker for cognitive recovery in acute schizophrenia: 12-week results from a prospective longitudinal study, Psychopharmacology, 235, 1191, 10.1007/s00213-018-4835-6 · DOI
Cited by
Colucci-D’Amato, L., Speranza, L., & Volpicelli, F. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207777 · Cited by 991
Brain-derived neurotrophic factor and schizophrenia
Di Carlo, P., Punzi, G., & Ursini, G. (2019) · Psychiatric Genetics · doi:10.1097/ypg.0000000000000237 · Cited by 110
“As recently reviewed (Han and Deng, 2018), BDNF Val66Met may play a critical role in metabolic disorders associated with antipsychotic treatment in patients with schizophrenia, and indeed rs6265 has been independently associated with eating disorders (Bonaccorso et al.”
BackgroundBDNF as a Biomarker of Cognition in Schizophrenia/Psychosis: An Updated Review
Nieto, R. R., Carrasco, A., Corral, S., Castillo, R., Gaspar, P. A., Bustamante, M. L., & Silva, H. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.662407 · Cited by 83
Metadata
- Authors
- Han, M., & Deng, C.
- Venue
- Neuroscience Letters
- Publisher
- Elsevier BV
- Published
- 2020-05
- Volume
- 726
- Pages
- 133870
- ISSN
- 0304-3940 (ISSN-L)
- OpenAlex
- W2896381820
- Cited by
- 41
- References
- 3
- FWCI
- 2.08
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Funders
- National Health and Medical Research Council
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.